Literature DB >> 3771427

The activity of drugs against Giardia intestinalis in neonatal mice.

P F Boreham, R E Phillips, R W Shepherd.   

Abstract

The activities of 12 5-nitroimidazoles and ten other compounds have been compared against Giardia intestinalis stock BRIS/83/HEPU/106 in a suckling mouse model. Ronidazole, satranidazole and fexinidazole were the most active compounds being 2.8, 2.0 and 2.0 times more active than tinidazole respectively and warrant further investigation as potential chemotherapeutic agents. The results obtained in mice are consistent with the known activity of nitroimidazoles in man. There was a strong positive correlation between these results and previous in-vitro studies obtained using a 3H-thymidine uptake assay, indicating that in-vitro studies are of value in predicting in-vivo responses.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3771427     DOI: 10.1093/jac/18.3.393

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  4 in total

1.  Orally administered Giardia duodenalis extracts enhance an antigen-specific antibody response.

Authors:  L A Dunn; J A Upcroft; E V Fowler; B S Matthews; P Upcroft
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

2.  Impaired parasite attachment as fitness cost of metronidazole resistance in Giardia lamblia.

Authors:  Noa Tejman-Yarden; Maya Millman; Tineke Lauwaet; Barbara J Davids; Frances D Gillin; Linda Dunn; Jacqueline A Upcroft; Yukiko Miyamoto; Lars Eckmann
Journal:  Antimicrob Agents Chemother       Date:  2011-08-08       Impact factor: 5.191

3.  Susceptibility of Giardia lamblia to aminoglycoside protein synthesis inhibitors: correlation with rRNA structure.

Authors:  T D Edlind
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

4.  Physical map of a 2 Mb chromosome of the intestinal protozoan parasite Giardia duodenalis.

Authors:  N Chen; J A Upcroft; P Upcroft
Journal:  Chromosome Res       Date:  1994-07       Impact factor: 5.239

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.